Comment on: "Codelivery of Gemcitabine and MUC1 Inhibitor Using PEG-PCL Nanoparticles for Breast Cancer Therapy"

Mol Pharm. 2023 Feb 6;20(2):1447-1448. doi: 10.1021/acs.molpharmaceut.2c00903. Epub 2022 Dec 28.

Author

Tian Tian¹

Affiliation

¹ Department of Neurology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China.

PMID: 36576337
DOI: 10.1021/acs.molpharmaceut.2c00903

No abstract available

Publication types

Comment

MeSH terms

Antineoplastic Agents* / pharmacology
Antineoplastic Agents* / therapeutic use
Breast Neoplasms* / drug therapy
Cell Line, Tumor
Drug Carriers / therapeutic use
Female
Gemcitabine
Humans
Mucin-1
Nanoparticles*
Polyesters
Polyethylene Glycols / therapeutic use

Substances

Gemcitabine
Antineoplastic Agents
Polyethylene Glycols
Polyesters
Drug Carriers
MUC1 protein, human
Mucin-1